Share on StockTwits

Cambrex Corp. (NYSE:CBM) issued an update on its FY14 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.99-1.10 for the period, compared to the Thomson Reuters consensus estimate of $1.11, AnalystRatings.Net reports. The company issued revenue guidance of approx $340-352 million, compared to the consensus revenue estimate of $349.62 million.

Cambrex Corp. (NYSE:CBM) opened at 22.18 on Tuesday. Cambrex Corp. has a 52 week low of $11.39 and a 52 week high of $22.24. The stock’s 50-day moving average is $18.13 and its 200-day moving average is $16.29. The company has a market cap of $670.8 million and a P/E ratio of 10.72.

Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings results on Tuesday, February 11th. The company reported $0.30 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.30. The company had revenue of $103.00 million for the quarter, compared to the consensus estimate of $95.25 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 46.3% on a year-over-year basis. On average, analysts predict that Cambrex Corp. will post $0.84 earnings per share for the current fiscal year.

A number of research firms have recently commented on CBM. Analysts at Zacks upgraded shares of Cambrex Corp. from a neutral rating to an outperform rating in a research note on Thursday, January 30th. They now have a $20.10 price target on the stock. Analysts at First Analysis upgraded shares of Cambrex Corp. from an equal weight rating to an overweight rating in a research note on Tuesday, January 28th.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.